DAY101 Monotherapy or in Combination With Other Therapies for Patients With Solid Tumors
Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
This is a Phase 1b/2, multi-center, open label umbrella study of patients ≥12 years of age
with recurrent or progressive solid tumors with alterations in the key proteins of the
RAS/RAF/MEK/ERK pathway.